For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240822:nRSV3376Ba&default-theme=true
RNS Number : 3376B Benchmark Holdings PLC 22 August 2024
22 August 2024
Information within this announcement is deemed by the Company to constitute
inside information under the Market Abuse Regulations (EU) No. 596/2014
Benchmark Holdings plc
("Benchmark", the "Company" or the "Group")
Q3 Results
(Three months and nine months ended 30 June 2024)
Solid performance in Genetics and Advanced Nutrition amidst continuing soft
shrimp markets
Completed steps to streamline Health and transition Ectosan® Vet and
CleanTreat® business model
In compliance with the terms of the Company's unsecured Green bond, which
requires it to publish quarterly financial information, Benchmark, the
aquaculture biotechnology business, announces its unaudited results for the
three months ended 30 June 2024 (the "Period" or "Q3 FY24"), which constitutes
the third quarter for the fiscal year ("FY") 2024, and its year to date
unaudited results for the nine months ended 30 June 2024 ("Q3 YTD FY24"). All
Q3 FY24, Q3 FY23, Q3 YTD FY24 and Q3 YTD FY23 figures quoted in this
announcement are based on unaudited accounts.
Financial highlights
Q3 FY24
· Group revenues of £30.7m were 10% below prior year (-7% at constant
exchange rate "CER") driven by:
o Advanced Nutrition: good trading with 4% increase against the prior year
(+11% CER) despite continuing softness in the shrimp market
o Genetics: solid trading albeit revenues were 18% (17% CER) below Q3 FY23
reflecting a shift from direct egg sales to indirect sales through Salmar
Genetics, the Group's JV in Norway, as well as a timing difference in harvest
income compared to last year
o Health: revenues were 43% below last year (-41% CER) reflecting the
decommissioning of the two CleanTreat® units as part of the planned
transition to a new business model for Ectosan® Vet and CleanTreat®
· 15% increase in Adjusted EBITDA excluding fair value ("FV") movement
of biological assets (+19% CER) driven by:
o Progress across all Genetics growth vectors including Chile, shrimp and
genetic services
o Higher contribution from the Group's JV in Norway, and
o Positive impact of streamlined organisation and infrastructure in Health
· Adjusted EBITDA margin excluding FV movement of biological assets was
15% (Q3 FY23: 12%) resulting from 28% margin in Genetics (Q3 FY23: 16%), 11%
margin in Advanced Nutrition (Q3 FY23: 21%) and breakeven in Health (Q3 FY23:
-27%)
· Operating Loss was £6.5m (Q3 FY23: £4.0m loss)
· Ample liquidity and headroom
o Cash of £17.0m and liquidity of £34.2m (cash and available facility) as
of 30 June 2024
o Net debt (excluding lease liabilities) £63.9m as at 30 June 2024 (31
March 2024: £56.8m; 30 September 2023: £45.6m)
Q3 YTD FY24
· Group revenues were £110.9m, 17% below the prior year (-11% CER)
due to:
o Soft conditions in the shrimp markets throughout the year
o Normalised egg volumes in Genetics against last year coupled with shift from
direct egg sales to indirect sales through the Group's JV in Norway
o Lower Health revenues following the decommissioning of the two CleanTreat®
units
· Adjusted EBITDA excluding FV movement of biological assets was 17%
below the prior year (-10% CER) with an increase in Genetics offset by a
decrease in Advanced Nutrition and Health
· Adjusted EBITDA margin excluding FV movement from biological assets
was in line with last year at 20% (Q3 YTD FY23: 20%) resulting from 24% margin
in Genetics (Q3 YTD FY23: 18%), 20% margin in Advanced Nutrition (Q3 YTD FY23:
24%) and 17% margin in Health (Q3 YTD FY23: 25%)
· Operating loss was £10.2m (Q3 YTD FY24: £3.0m)
Business Area Highlights
· Advanced Nutrition - good trading in Q3 FY24 against backdrop of
continuing softness in the shrimp market
o Q3 revenues were 4% ahead of the prior year with good trading partially
offset by forex headwinds (+11% CER)
o YTD revenues were 1% above the prior year on a constant exchange rate; 7%
below including forex impact
o Q3 Adjusted EBITDA was lower at £1.8m (Q3 FY23: £3.4m) reflecting lower
margins due to product mix and higher logistics costs as a result of temporary
disruption to trading routes with freight vessels avoiding the regional
insecurity of the Suez Canal by travelling around Cape of Good Hope. Adjusted
EBITDA margin was 11% (Q3 FY23: 21%)
o YTD Q3 FY24 Adjusted EBITDA margin was 20% (YTD Q3 FY23: 24%)
o The shrimp market remained soft with green shoots not yet translating into
market recovery. Despite this the fundamentals remain strong.
§ We maintain commercial focus and take action to optimise our performance
and competitive position including by expanding our product portfolio and
strengthening our presence in key markets
§ Regulators and market participants taking steps to support the aquaculture
sector e.g. reduction of import duty on aquaculture supplies in India and
development of value-added shrimp products in Ecuador to stimulate exports
· Genetics - increase in underlying profitability driven by progress
across all growth vectors - Chile, shrimp and genetic services
o Q3 revenues 18% below Q3 FY23 (-17% CER) driven by shift against last year
from direct egg sales to indirect sales through the Group's JV in Norway, the
benefit of which is reflected in EBITDA and timing difference in harvest
income compared to last year
o YTD Q3 revenues -17% (-13% CER) compared to last year which benefitted
from supply constraints in the market in the first part of the year
o 46% increase in Q3 Adjusted EBITDA excluding FV movement of biological
assets driven by:
§ Chile - Adjusted EBITDA excluding FV movement of £0.5m (Q3 FY23: £0.9m
loss)
§ Shrimp - Adjusted EBITDA loss reduced from £0.8m to £0.5m
§ Higher contribution from the JV in Norway
o Q3 Adjusted EBITDA margin excluding FV movement 28% (Q3 FY23: 16%)
o YTD Q3 Adjusted EBITDA margin excluding FV movement was 24% (Q3 YTD FY23:
18%)
· Health - significant restructuring and streamlining as part of
transition to new business model for Ectosan® Vet and CleanTreat®
o Q3 revenues 43% below last year (-41% CER) reflecting the decommissioning
of the CleanTreat® units as part of the planned transition to a new business
model for Ectosan® Vet and CleanTreat®
§ Salmosan® Vet revenue increased 17%
o Q3 Adjusted EBITDA loss reduced to nil (Q3 FY23 loss: £1.0m) showing the
positive impact of restructuring actions in the seasonally quiet third quarter
o YTD Q3 Adjusted EBITDA of £2.3m (YTD Q3 FY23: £5.6m); YTD Q3 Adjusted
EBITDA margin of 17% (YTD Q3 FY23: 25%)
o Business rightsized to deliver Salmosan® Vet solution which will drive
profitability and cash generation post restructuring
o Maintained capability to deploy Ectosan® Vet and CleanTreat®, a proven
effective solution to address sea lice, subject to customer investment in
CleanTreat® infrastructure
Current trading and outlook
· Trading well against backdrop of market headwinds in Advanced
Nutrition and the restructuring in Health which have an impact on short term
performance but support near and long term prospects
o Good visibility of salmon egg deliveries in Genetics for the remainder of
the year and continued progress in growth vectors
o Resilience in Advanced Nutrition underpinned by commercial focus and
streamlined efficient organisation
o Profitable and cash positive Health business following restructuring and
underpinned by good performance of Salmosan® Vet
· Actions taken during the year bring all business areas to
profitability and set them on the path to deliver shareholder value
Financial Summary (continuing operations)
£m Q3 FY23 % CER YTD Q3 FY24 YTD Q3 FY23 % CER**
Q3 FY24 Q3 FY24 Restated* Q3 YTD FY24
Revenue 30.7 34.2 -7% 110.9 132.9 -11%
-10% -17%
Adjusted
Adjusted EBITDA(1) 4.5 5.4 -14% 21.3 28.1 -17%
-17% -24%
Adj. EBITDA excluding biological asset fair value movements 4.6 4.0 +19% 21.9 26.4 -10%
+15% -17%
Adjusted Operating Profit/(Loss)(2) (0.4) 0.2 -216 5.7 12.6 -43%
-278% -55%
Adj. Operating profit excluding biological asset fair value movements (0.3) (1.2) +84% 6.3 10.9 -28%
+76% -43%
Statutory
Operating loss (6.5) (4.0) -57% (10.2) (3.0) -189%
-61% -238%
Loss before tax (9.4) (4.3) -118% (17.3) (5.4) -191%
-121% -217%
Basic loss per share (p) (1.34) (0.64) (2.55) (1.04)
Net debt(3) (66.9) (66.9)
Net debt(3) excluding lease liabilities (45.7) (45.7)
Business Area summary
£m Q3 FY23 % CER YTD Q3 FY24 YTD Q3 FY23 % CER**
Q3 FY24 Q3 FY24 YTD Q3 FY24
Revenue
Advanced Nutrition 16.8 16.1 +11% 57.2 61.4 +1%
+4% -7%
Genetics 11.8 14.4 -17% 40.2 48.7 -13%
-18% -17%
Health 2.2 3.8 -41% 13.6 22.9 -38%
-43% -40%
Adjusted EBITDA(1)
Advanced Nutrition 1.8 3.4 -43% 11.7 14.9 -14%
-47% -22%
Genetics 3.2 3.7 -13% 9.1 10.3 -6%
-14% -11%
- Net of fair value movements in biological assets 3.3 2.3 +45% 9.7 8.6 +20%
+46% +13%
Health 0.0 (1.0) +104 2.3 5.6 -58%
+105% -60%
*Q3 2023 numbers were restated to reflect certain operations of the Group that
were classified as discontinued operations and divested during that period in
line with IFRS 5 (See Note 5)
** Constant exchange rate (CER) figures derived by retranslating current year
figures using previous year's foreign exchange rates
(1) Adjusted EBITDA is EBITDA (earnings before interest, tax, depreciation and
amortisation and impairment), before exceptional items including acquisition
related expenditure
(2) Adjusted Operating Profit is operating loss before exceptional items
including acquisition related items and amortisation of intangible assets
excluding development costs
(3) Net debt is cash and cash equivalents less loans and borrowings
Strategic review
In January 2024, the Company announced that the Board had unanimously decided
to undertake a formal review of the Company's strategic options including a
potential formal sale process. This process remains ongoing and further
updates will be provided as appropriate.
Trond Williksen, CEO, commented:
"Our two largest business areas, Advanced Nutrition and Genetics, performed
well in Q3. In Genetics, it is particularly pleasing to see continued progress
in our Chilean business as well as the positive results of the recent
reorganisation of our shrimp genetics activities. Our Advanced Nutrition
business remains resilient to the continuing soft conditions in the shrimp
markets and is well positioned for market recovery.
Having streamlined our Health business, rightsizing it to focus on Salmosan®
Vet during the transition period to a new business model for Ectosan® Vet and
CleanTreat®, we now have a profitable business which maintains its capability
to deliver Ectosan® Vet and CleanTreat®."
Presentation for analysts and institutional investors at 08.00 UK time (09.00
CEST)
Trond Williksen, Chief Executive Officer and Septima Maguire, Chief Financial
Officer will host a presentation for analysts and institutional investors on
the day at 08.00 UK time (09.00 CEST).
The presentation will be held in person at Haakon Vlls Gate 2, Oslo, Norway.
To register your interest, please contact benchmark@mhpgroup.com
(mailto:benchmark@mhpgroup.com)
A live webcast of the presentation will be available for analysts and
investors to join remotely at the following
link: https://channel.royalcast.com/landingpage/hegnarmedia/20240822_11/
(https://protect.checkpoint.com/v2/___https:/channel.royalcast.com/landingpage/hegnarmedia/20240822_11/___.bXQtcHJvZC1jcC1ldXcyLTE6bmV4dDE1OmM6bzplZGE4OTQzOTZmMGU1OTgxNDk1MDkzOWE1YTAzMzdiNTo2OmEwZTM6ZTM5NGExMjdmYzhlMDk3YjU2MGI4ZmE0M2RkOGY4MjFiYWNlMGFhOTJkNDEzOTQ3NGEzOGU4NDY0NTYwMjY0MDpoOkY6Tg)
A live webcast of the presentation will be available for analysts and
investors to join remotely at the following link:
link: https://channel.royalcast.com/landingpage/hegnarmedia/20240822_11/
(https://protect.checkpoint.com/v2/___https:/channel.royalcast.com/landingpage/hegnarmedia/20240822_11/___.bXQtcHJvZC1jcC1ldXcyLTE6bmV4dDE1OmM6bzplZGE4OTQzOTZmMGU1OTgxNDk1MDkzOWE1YTAzMzdiNTo2OmEwZTM6ZTM5NGExMjdmYzhlMDk3YjU2MGI4ZmE0M2RkOGY4MjFiYWNlMGFhOTJkNDEzOTQ3NGEzOGU4NDY0NTYwMjY0MDpoOkY6Tg)
A copy of the presentation can be found on the Company's website
https://www.benchmarkplc.com/investors/reports-presentations/
Equity Development webcast at 12.00 UK time (13:00 CEST)
Trond Williksen, Chief Executive Officer and Septima Maguire, Chief Financial
Officer will host a second webcast for retail investors and wealth managers on
the day at 12.00 UK time (13:00 CEST). The webcast is open to all existing and
potential shareholders.
To register please visit:
https://www.equitydevelopment.co.uk/news-and-events/benchmark-investor-presentation-22aug2024
(https://www.equitydevelopment.co.uk/news-and-events/benchmark-investor-presentation-22aug2024)
A recording of the presentation will be available after the event on the
Equity Development website
(https://protect.checkpoint.com/v2/___https:/www.equitydevelopment.co.uk/research/tag/benchmark-holdings___.bXQtcHJvZC1jcC1ldXcyLTE6bmV4dDE1OmM6bzo3ZGQwM2M5ZGE1ODFhNGFkZmQzY2M5ODhkNzJhODJiNzo2OmYxNDk6MTY2MmI4MDMwNmRkMmU4ZTg4Y2VhODdlYjljMDkyMTc0MTVkYjU0MmUzYzI4MGVjOTQ2Y2YwMzRmYzExZDI0ZjpwOlQ6Tg)
.
(https://protect.checkpoint.com/v2/___https:/www.equitydevelopment.co.uk/research/tag/benchmark-holdings___.bXQtcHJvZC1jcC1ldXcyLTE6bmV4dDE1OmM6bzo3ZGQwM2M5ZGE1ODFhNGFkZmQzY2M5ODhkNzJhODJiNzo2OmYxNDk6MTY2MmI4MDMwNmRkMmU4ZTg4Y2VhODdlYjljMDkyMTc0MTVkYjU0MmUzYzI4MGVjOTQ2Y2YwMzRmYzExZDI0ZjpwOlQ6Tg)
Enquiries:
For further information, please contact:
Benchmark Holdings plc benchmark@mphc.com
Trond Williksen, CEO
Septima Maguire, CFO
Ivonne Cantu, Investor Relations
Deutsche Numis (Nominated Adviser and Broker) Tel: 020 7260 1000
Freddie Barnfield, Duncan Monteith, Sher Shah
MHP Tel: +44 7831 406117
Katie Hunt, Reg
Hoare
benchmark@mhpgroup.com (mailto:benchmark@mhpgroup.com)
About Benchmark
Benchmark is a market leading aquaculture biotechnology company. Benchmark's
mission is to drive sustainability in aquaculture by delivering products and
solutions in genetics, advanced nutrition and health which improve yield,
growth and animal health and welfare.
Through a global footprint in 26 countries and a broad portfolio of products
and solutions, Benchmark addresses many of the major aquaculture species -
salmon, shrimp, sea bass and sea bream, and tilapia - in all the major
aquaculture regions around the world. Find out more at www.benchmarkplc.com
Management Report
Q3 FY24 commentary
The Group performed well in Q3 FY24 with solid trading in its two largest
business areas of Advanced Nutrition and Genetics, noting that Q3 is a low
season quarter for the Group in totality. In Health we continued to
streamline the business, rightsizing our resources to support our Salmosan®
Vet activities during the planned transition to a new business model for
Ectosan® Vet and CleanTreat®. The restructuring of Health was completed post
period end and will result in significant immediate cost savings and a cash
positive business. We have retained the capabilities to deploy Ectosan® Vet
and CleanTreat® onto customer infrastructure be it a barge or integrated
wellboat solution, both of which we are able to support, but now with very low
financial exposure. Ectosan® Vet and CleanTreat® remains a compelling
solution to the sea lice pressure experienced in the industry.
The Group reported revenues of £30.7m in the quarter, 10% below the prior
year (-7% CER). This resulted from revenue growth in Advanced Nutrition of 4%
(+11% CER) offset by 18% lower revenues in Genetics (-17% CER) and a 43% drop
in Health revenues (-41% CER) following the decommissioning of the
CleanTreat® units. The drop in Genetics revenue is due to a shift from
direct egg sales to indirect sales through the Company's JV in Norway, the
benefit of which is reflected in EBITDA, as well as a difference in the timing
of harvest income against the prior year and lower ancillary revenues.
Adjusted EBITDA excluding fair value movement of biological assets was £4.6m,
15% ahead of the prior year (+19% CER) driven by a higher Adjusted EBITDA
excluding fair value uplift in Genetics (+46%) reflecting progress across all
growth vectors - Chile, shrimp and genetic services - and higher JV profits,
together with the positive impact of the restructuring in Health. This was
partially offset by Advanced Nutrition which reported lower Adjusted EBITDA
reflecting a change in product mix and higher costs associated with the
temporary disruption of freight routes due to geopolitical conflicts in the
Suez Canal.
Operating costs for the Group of £9.9m were 6% below last year (Q3 FY23:
£10.5m) with a decrease in Genetics, Health and Corporate overheads and a
small increase in Advanced Nutrition. R&D expenses of £1.4m were broadly
in line with the prior year (Q3 FY23: £1.5m). The Group incurred £2.6m of
exceptional costs in Q3 FY24, including exceptional restructuring costs of
£1.2m relating to the formal review of the Company's strategic options and
other restructuring actions taken.
Depreciation and amortisation decreased to £8.4m (Q3 FY23: £8.9m), taking
Group operating loss for the quarter to £6.5m (Q3 FY23: £4.0m). The
Adjusted Operating loss excluding fair value movements in biological assets
was £0.3m (Q3 FY23: £1.2m loss).
Net finance costs were £2.9m, significantly above the comparative period (Q3
FY23: £0.2m) which benefitted from credits from the ineffective portion of
the movement in the fair value of the derivative instrument and forex
movements. Absent those movements, interest expense including lease interest
was at a similar level to the prior year. As a result of these year-on-year
movements, the loss before tax in the quarter was £9.4m (Q3 FY23: £4.3m).
The tax charge in the period was a £0.5m (Q3 FY23: £0.1m credit). The
resulting loss after tax for the quarter was £10.0m (Q3 FY23: loss £4.2m).
The Group reported a net cash inflow from operating activities of £1.2m (Q3
FY23: £3.9m), Working capital was an outflow of £1.3m (Q3 F2Y23: £1.1m).
Net cash used in investing activities was £0.6m (Q3 FY23: £0.2m inflow) of
which capex was £0.8m (Q3 FY23: £1.1m) offset by proceeds from sale of fixed
assets. During the period, net interest paid was £2.4m and tax paid was
£2.1m. Cash used in financing activities was £2.1m (Q3 FY23: £6.8m). The
Group maintains ample liquidity and headroom with cash of £17m and liquidity
of £34.2m (cash and available liquidity) as of 30 June 2024.
Q3 YTD FY24 Commentary
Q3 YTD FY24 the Group delivered revenue of £110.9m (Q3 YTD FY23: £132.9m)
with the drop resulting from lower revenues in Genetics against a strong FY23
which benefitted from supply constraints in the market, lower revenues in
Advanced Nutrition as a result of soft shrimp markets and a reduction in
Health following the decommissioning of the CleanTreat® units.
Adjusted EBITDA excluding fair value movements from biological assets was
£21.9m (Q3 YTD FY23: £26.4m) with Genetics reporting a 13% increase while
Advanced Nutrition and Health were down 22% and 60% respectively as a result
of lower revenues.
Operating costs were £30.2m, a 12% reduction from the prior year (Q3 YTD
FY23: £34.3m). Operating costs were down across all business areas as were
corporate overheads reflecting good cost control, initiatives to improve
efficiency and a resizing of the Health business. R&D expenses of £4.5m
were in line with the prior year. Total R&D investment including
capitalised development costs was £4.6m (Q3 YTD FY23: £4.9m).
The Adjusted EBITDA margin (excluding fair value movement from biological
assets) was 20% (Q3 YTD FY23: 20%). Depreciation and amortisation decreased
5% from the comparative period last year to £26.5m (Q3 YTD FY23: £27.9m),
leaving the operating loss in the period at £10.2m (Q3 YTD FY22: £3.0m).
There was a significant increase in net finance costs for Q3 YTD FY24 to
£7.1m (Q3 YTD FY23: £2.4m), primarily as a result of income from movements
in hedge accounting in the prior year, coupled with increased interest costs
due to higher borrowings during the current year. This is slightly offset by
differences in foreign exchange gains and losses year on year. This led to a
loss before tax of £17.3m (Q3 YTD FY23: £5.4m). The tax charge in the period
of £1.4m was in line with the prior year, leaving loss from continuing
operations at £18.7m (Q3 YTD FY23: £6.9m).
Year to date, the Group reported a net operating cash outflow of £2.8m after
a decrease in working capital of £14.1m mainly due to a reduction in trade
payables. Net cash outflow from investing activities was £2.1m, including
capex of £2.7m including intangibles and capitalised development costs. Our
cash position at the end of the period was £17.0m and liquidity of £34.2m.
Business Area Commentary
Advanced Nutrition
Advanced Nutrition revenues were £16.8m, 4% above Q3 FY23 and 11% above last
year on a constant exchange rate basis. This is particularly positive against
a backdrop of continuing softness in the global shrimp market and demonstrates
the success of our commercial focus and the resilience of our business. By
product area, sales of Artemia were +4%, Diets +7% and Health -6% against Q3
FY23.
Our gross profit margin in Advanced Nutrition of 48% (Q3 FY23: 59%) reflects a
change in product mix and increased freight costs owing to global geopolitical
conflicts. Operating costs were also slightly above the prior year (+3%) and
as a result Q3 FY24 Adjusted EBITDA was £1.8m (Q3 FY23: £3.4m).
YTD Q3 FY24 revenue was £57.2m, 7% behind the prior year (+1% CER) and
Adjusted EBITDA was 22% below (CER -14%) prior year at £11.7m.
Strategically we continue to take steps to optimise our operations, to expand
our product portfolio to address specific market opportunities and have plans
to strengthen our presence in certain key markets both directly and through
collaborations.
The shrimp market remained soft in the period with green shoots in certain
markets not yet translating into market recovery. Nevertheless, we remain
confident that we continue to be resilient and well positioned as the market
recovers. At a macro sector level certain countries are taking steps to
support the industry including a reduction in custom duty on aquaculture
supplies in India and a focus on processed high value shrimp products in
Ecuador. These are structural measures which will support the development and
profitability of the industry in the longer term from which we expect to
benefit.
Genetics
Genetics delivered solid trading in Q3 FY24 despite revenues of £11.8m being
18% below the prior year (-17% CER). This was driven mainly by lower harvest
income due to the timing of the harvest, and a shift from direct egg sales to
indirect sales through our JV in Norway in the period. Direct sales volume of
salmon eggs was 60m, 8m below Q3 FY23. Total volume of egg sales including
direct sales and indirect sales made through the Group's JV in Norway was 69m,
marginally below the prior year (Q3 FY23: 70m eggs). YTD Q3 FY24 total
volume of eggs was 258m (YTD Q3 FY23: 275m).
Notably all growth vectors performed well in the period. Revenues from Chile
increased 12% taking the Adjusted EBITDA excluding fair value movement from a
loss of £0.9m in Q3 FY23 to a profit of £0.5m. This result also reflects
higher capitalisation of production costs associated with our biological
assets in Chile as we gain commercial traction and there is increased
visibility of future sales. In shrimp our ongoing work to develop local lines
is making good progress and we are starting to benefit from the commercial
integration of our shrimp portfolio led by our Advanced Nutrition business.
While this is not yet evident in material sales volumes, the reorganisation
and integration resulted in significant cost savings reducing the Adjusted
EBITDA loss for our shrimp genetics business from a loss of £0.8m in Q3 FY23
to a loss of £0.5m in the period.
Adjusted EBITDA for Q3 FY24 excluding fair value movements of biological
assets was up 46% (+45% CER) to £3.3m (Q3 FY23: £2.3m) due to a higher
contribution from Salmar Genetics, the Group's JV in Norway, improved
performance across all growth vectors and higher capitalisation of production
costs associated with biological assets resulting in a favourable movement
against last year.
YTD Q3 FY24 revenues were £40.2m 13% CER below the prior year which
benefitted from supply constraints in the market. Adjusted EBITDA excluding
fair value movement of biological assets was £9.7m (YTD Q3 FY23: £10.6m).
The Adjusted EBITDA margin excluding fair value movement of biological assets
was 24% (YTD Q3 FY23: 19%).
Health
Revenues in Q3 FY23 were £2.2m, 43% below the prior year (Q3 FY23: £3.8m).
Sales from Ectosan® Vet and CleanTreat® were £0.9m (Q3 FY23: £2.7m).
Salmosan® sales were 17% above the prior year at £1.2m.
During the quarter we took the second of the two platform supply vessels (PSV)
carrying the CleanTreat® systems out of service and we have streamlined the
rest of the organisation accordingly. As a result, Adjusted EBITDA was nil (Q3
FY23: loss of £1.0m) reflecting cost savings achieved through the
restructuring. We have maintained the capabilities and expertise to deploy
Ectosan® Vet and CleanTreat® subject to customer investment in the
CleanTreat® infrastructure be it a barge or an integrated wellboat.
Ectosan® Vet and CleanTreat® remains a proven, highly efficacious sea lice
solution capable of addressing the growing sea lice pressure. In addition to
its high efficacy, it offers salmon producers an environmentally friendly way
of treating sea lice with high fish health and welfare credentials.
The cost savings associated with the restructuring offset the reduction in
revenues and the business area delivered Adjusted EBITDA of nil (Q3 FY23: 1.0m
loss).
YTD revenue was £13.6m (Q3 YTD FY23: £22.9m) reflecting changes in the
business area. YTD Adjusted EBITDA was £2.3m (YTD Q3 FY23 £5.6m).
Outlook
The Group is trading well against a backdrop of market headwinds in Advanced
Nutrition and the restructuring in Health which have an impact on short term
performance but support near and long term prospects. For the remainder of the
year there is good visibility of salmon egg deliveries in Genetics albeit
below last year when we benefitted from supply constraints in the market, and
expect continued progress in the Genetics growth vectors with the clear aim of
making them increasingly profitable over time.
In Advanced Nutrition we expect market conditions to remain soft for the
remainder of the year, but we are confident that we have a resilient,
efficient organisation capable of operating well in this environment and which
is well positioned to benefit from future market recovery.
In Health, following the streamlining implemented this year we expect to have
a profitable and cash positive business underpinned by good performance of
Salmosan® Vet.
Overall, the actions and progress achieved this year will bring all business
areas to profitability and on a path to deliver shareholder value in the near
and long term.
All figures in £000's Notes Q3 2024 Q3 2023 YTD Q3 2024 YTD Q3 2023 FY 2023
(unaudited)
Restated*
(unaudited)
Restated*
(audited)
(unaudited)
(unaudited)
Revenue 4 30,689 34,224 110,913 132,883 169,476
Cost of sales (15,071) (16,715) (56,047) (66,052) (82,726)
Gross profit 15,618 17,509 54,866 66,831 86,750
Research and development costs (1,409) (1,493) (4,468) (4,478) (6,069)
Other operating costs (9,879) (10,521) (30,231) (34,292) (45,157)
Share of profit/(loss) of equity-accounted investees, net of tax 185 (55) 1,170 1 (32)
Adjusted EBITDA² 4,515 5,440 21,337 28,062 35,492
Exceptional - restructuring, acquisition and disposal related items 6 (2,586) (530) (5,065) (3,218) (3,904)
EBITDA¹ 1,929 4,910 16,272 24,844 31,588
Depreciation and impairment (4,284) (4,626) (13,851) (13,640) (18,409)
Amortisation and impairment (4,140) (4,318) (12,629) (14,230) (18,495)
Operating loss (6,495) (4,034) (10,208) (3,026) (5,316)
Finance cost 7 (3,536) (2,972) (8,977) (13,180) (15,048)
Finance income 7 612 2,746 1,905 10,762 7,670
Loss before taxation (9,419) (4,260) (17,280) (5,444) (12,694)
Tax on loss 8 (529) 76 (1,439) (1,407) (3,365)
Loss from continuing operations (9,948) (4,184) (18,719) (6,851) (16,059)
Discontinued operations
Loss from discontinued operations, net of tax 5 - (438) - (1,170) (5,505)
(9,948) (4,622) (18,719) (8,021) (21,564)
Loss for the year attributable to:
- Owners of the parent (9,913) (4,760) (18,861) (8,763) (23,146)
- Non-controlling interest (35) 138 142 742 1,582
(9,948) (4,622) (18,719) (8,021) (21,564)
Earnings per share
Basic loss per share (pence) 9 (1.34) (0.64) (2.55) (1.20) (3.16)
Diluted loss per share (pence) 9 (1.34) (0.64) (2.55) (1.20) (3.16)
Earnings per share - continuing operations
Basic loss per share (pence) 9 (1.34) (0.58) (2.55) (1.04) (2.41)
Diluted loss per share (pence) 9 (1.34) (0.58) (2.55) (1.04) (2.41)
Adjusted EBITDA from continuing operations 4,515 5,440 21,337 28,062 35,492
Adjusted EBITDA from discontinued operations 5 - (353) - (915) (1,254)
Total Adjusted EBITDA 4,515 5,087 21,337 27,147 34,238
1 EBITDA - Earnings before interest, tax, depreciation, amortisation, and
impairment
2 Adjusted EBITDA - EBITDA before exceptional items including acquisition
related items
* Q3 2023 numbers were restated to reflect certain operations of the Group
that were classified as discontinued operations during FY23 in line with IFRS
5. (See Note 5).
The accompanying notes are an integral part of this consolidated financial
information.
All figures in £000's Q3 2024 Q3 2023 YTD Q3 2024 YTD Q3 2023 FY 2023
(unaudited)
Restated
(unaudited)
Restated
(audited)
(unaudited)
(unaudited)
Loss for the period (9,948) (4,622) (18,719) (8,021) (21,564)
Other comprehensive income
Items that are or may be reclassified subsequently to profit or loss
Foreign exchange translation differences (497) (11,153) (11,489) (35,166) (23,475)
Cash flow hedges - changes in fair value 701 2,093 (1,644) 1,794 (2,123)
Cash flow hedges - reclassified to profit or loss (475) (273) 1,139 (565) 2,623
Total comprehensive income for the period (10,219) (13,955) (30,713) (41,958) (44,539)
Total comprehensive income for the period attributable to:
- Owners of the parent (10,270) (14,204) (30,607) (42,250) (45,404)
- Non-controlling interest 51 249 (106) 292 865
(10,219) (13,955) (30,713) (41,958) (44,539)
Total comprehensive income for the period attributable to owners of the
parent:
- Continuing operations (10,270) (13,705) (30,607) (40,753) (39,777)
- Discontinued operations* - (499) - (1,497) (5,627)
(10,270) (14,204) (30,607) (42,250) (45,404)
*Total comprehensive income for the period relating to discontinued operations
for Q3 2024 includes the loss of £nil (Q3 2023: £438,000) and foreign
exchange loss of £nil (Q3 2023: £61,000). FY23 includes the loss of
£5,505,000 and foreign exchange loss of £122,000.
The accompanying notes are an integral part of this consolidated financial
information.
30 June 2024 30 June 2023 30 September 2023
All figures in £000's Notes (unaudited) (unaudited) (audited)
Assets
Property, plant and equipment 66,505 71,880 73,411
Right-of-use assets 12,284 21,755 19,804
Intangible assets 186,841 205,312 206,077
Equity-accounted investees 4,833 3,028 3,558
Other investments 1 13 14
Biological and agricultural assets 2,748 21,688 18,406
Non-current assets 273,212 323,676 321,270
Inventories 24,096 26,244 25,269
Biological and agricultural assets 42,507 21,301 27,586
Trade and other receivables 50,590 47,858 59,795
Cash and cash equivalents 16,984 32,858 36,525
134,177 128,261 149,175
Assets held for sale 10 - 850 850
Current assets 134,177 129,111 150,025
Total assets 407,389 452,787 471,295
Liabilities
Trade and other payables (27,847) (32,034) (47,329)
Loans and borrowings 11 (15,571) (21,757) (20,045)
Corporation tax liability (4,101) (6,791) (6,422)
Provisions (2,007) (1,557) (1,280)
Current liabilities (49,526) (62,139) (75,076)
Loans and borrowings 11 (76,482) (77,960) (81,954)
Other payables (7,713) (4,908) (6,842)
Deferred tax (20,242) (22,755) (24,106)
Provisions - - (700)
Non-current liabilities (104,437) (105,623) (113,602)
Total liabilities (153,963) (167,762) (188,678)
Net assets 253,426 285,025 282,617
Issued capital and reserves attributable to owners of the parent
Share capital 12 740 739 739
Additional paid-in share capital 12 37,490 37,428 37,428
Capital redemption reserve 5 5 5
Retained earnings 166,087 197,168 183,489
Hedging reserve (708) 526 (203)
Foreign exchange reserve 43,706 43,520 54,947
Equity attributable to owners of the parent 247,320 279,386 276,405
Non-controlling interest 6,106 5,639 6,212
Total equity and reserves 253,426 285,025 282,617
The accompanying notes are an integral part of this consolidated financial
information.
Share Additional paid-in share capital Other Hedging Retained Total attributable Non- Total
capital
reserves*
reserve
earnings
to equity holders of
controlling
equity
parent
interest
£000 £000 £000 £000 £000 £000 £000 £000
As at 1 October 2023 (audited) 739 37,428 54,952 (203) 183,489 276,405 6,212 282,617
Comprehensive income/(loss) for the period
Profit/(loss) for the period - - - - (18,861) (18,861) 142 (18,719)
Other comprehensive loss - - (11,241) (505) - (11,746) (248) (11,994)
Total comprehensive income/(loss) for the period - - (11,241) (505) (18,861) (30,607) (106) (30,713)
Contributions by and distributions to owners
Share issue 1 62 - - - 63 - 63
Share-based payment - - - - 1,459 1,459 - 1,459
Total contributions by and distributions to owners 1 62 - - 1,459 1,522 - 1,522
Total transactions with owners of the Company 1 62 - - 1,459 1,522 - 1,522
As at 30 June 2024 (unaudited) 740 37,490 43,711 (708) 166,087 247,320 6,106 253,426
As at 1 October 2022 (audited) 704 420,824 77,710 (703) (185,136) 313,399 9,886 323,285
Comprehensive income/(loss)for the period
Profit/(loss) for the period - - - - (9,294) (9,294) 1,273 (8,021)
Other comprehensive income/(loss) - - (34,185) 1,229 - (32,956) (981) (33,937)
Total comprehensive income/(loss)for the period - - (35,185) 1,229 (9,294) (42,250) 292 (41,958)
Contributions by and distributions to owners
Share issue 35 12,985 - - - 13,020 - 13,020
Share issue costs recognised through equity - (2,146) - - - (2,146) - (2,146)
Cancellation of part of share premium account - (394,235) - - 394,235 - - -
Share-based payment - - - - 833 833 - 833
Total contributions by and distributions to owners 35 (383,396) - - 395,068 11,707 - 11,707
Changes in ownership
Acquisition of NCI - (3,470) (3,470) (4,539) (8,009)
Total changes in ownership interests - - - - (3,470) (3,470) (4,539) (8,009)
Total transactions with owners of the Company 35 (383,396) - - 391,598 8,237 (4,539) 3,698
As at 30 June 2023 (unaudited) 739 37,428 43,525 526 197,168 279,386 5,639 285,025
As at 1 October 2022 (audited) 704 420,824 77,710 (703) (185,136) 313,399 9,886 323,285
Comprehensive income/(loss) for the period
Profit/(loss) for the period - - - - (23,146) (23,146) 1,582 (21,564)
Other comprehensive income/loss) - - (22,758) 500 - (22,258) (717) (22,975)
Total comprehensive income/(loss) for the period - - (22,758) 500 (23,146) (45,404) 865 (44,539)
Contributions by and distributions to owners
Share issue 35 12,985 - - - 13,020 - 13,020
Share issue costs recognised through equity - (2,146) - - - (2,146) - (2,146)
Cancellation of part of share premium account - (394,235) - - 394,235 - - -
Share-based payment - - - - 1,006 1,006 - 1,006
Total contributions by and distributions to owners 35 (383,396) - - 395,241 11,880 - 11,880
Changes in ownership
Acquisition of NCI - - - - (3,470) (3,470) (4,539) (8,009)
Total changes in ownership interests - - - - (3,470) (3,470) (4,539) (8,009)
Total transactions with owners of the Company 35 (383,396) - - 391,771 8,410 (4,539) 3,871
As at 30 September 2023 (audited) 739 37,428 54,952 (203) 183,489 276,405 6,212 282,617
*Other reserves in this statement is an aggregation of capital redemption
reserve and foreign exchange reserve
The accompanying notes are an integral part of this consolidated financial
information.
All figures in £000's Q3 2024 Q3 2023 YTD Q3 2024 YTD Q3 2023 FY 2023
(unaudited)
(unaudited)
(unaudited)
(unaudited)
(audited)
Cash flows from operating activities
Loss for the period (9,948) (4,622) (18,719) (8,021) (21,564)
Adjustments for:
Depreciation and impairment of property, plant and equipment 2,854 2,115 7,921 6,363 8,453
Depreciation and impairment of right-of-use assets 1,430 2,587 5,930 7,505 10,260
Amortisation and impairment of intangible fixed assets 4,140 4,318 12,629 14,230 18,495
Profit on sale of property, plant and equipment (106) - (332) (36) (121)
Loss on sale of discontinued operation - - - - 3,774
Finance income (65) (1,226) (351) (4,195) (2,802)
Finance costs 2,916 2,806 8,311 7,173 10,535
Loss on disposal of investments in joint ventures - - (42) - -
Share of (profit)/loss of equity-accounted investees, net of tax (186) 54 (1,171) (1) 32
Foreign exchange (gains)/losses 345 (1,336) 10 (2,443) (1,814)
Share-based payment expense 654 358 1,458 833 1,005
Tax charge/(credit) 530 (75) 1,440 1,407 3,365
Decrease/(increase) in trade and other receivables 3,762 (2,299) 6,104 3,772 (6,570)
Decrease/(increase) in inventories (1,510) (268) 237 2,249 2,877
Increase in biological and agricultural assets (1,322) (1,296) (1,204) (403) (1,659)
(Decrease)/Increase in trade and other payables (2,415) 2,811 (18,372) (10,862) 3,909
Decrease /(increase) in provisions 164 (7) (839) (20) 386
1,243 3,920 3,010 17,551 28,561
Income taxes paid (2,101) (2,194) (5,818) (6,335) (8,556)
Net cash flows generated from operating activities (858) 1,726 (2,808) 11,216 20,005
Investing activities
Acquisition of subsidiaries - (48) - (48) (48)
Purchase of investments in associates (81) (52) (224) (359) (558)
Receipts from disposal of subsidiaries, joint ventures, and other investments - 1,250 37 1,250 1,250
Purchases of property, plant and equipment (628) (917) (2,398) (4,171) (5,953)
Purchase of intangibles (70) (43) (155) (120) (196)
Capitalised research and development costs (56) (183) (150) (380) (632)
Proceeds from sale of fixed assets 134 22 405 99 227
Cash receipts from swap contracts - - - - 11
Interest received 65 150 351 469 627
Net cash flows used in investing activities (636) 179 (2,134) (3,260) (5,272)
Financing activities
Proceeds of share issues - - - 13,000 13,000
Proceeds from exercise of share options 62 - 62 20 20
Share-issue costs recognised through equity - (496) - (2,146) (2,146)
Acquisition of minority interests in subsidiaries - - - (8,009) (8,009)
Proceeds from bank or other borrowings, net of borrowing fees 2,454 23 2,195 20,825 21,847
Repayment of bank or other borrowings (371) (967) (1,617) (17,527) (18,470)
Interest and finance charges paid (2,418) (2,654) (6,925) (6,736) (9,131)
Repayments of lease liabilities (1,817) (2,660) (7,185) (7,349) (9,438)
Net cash used in financing activities (2,090) (6,754) (13,470) (7,922) (12,327)
Net increase/(decrease) in cash and cash equivalents (3,584) (4,849) (18,412) 34 2,406
Cash and cash equivalents at beginning of period 20,759 38,647 36,525 36,399 36,399
Effect of movements in exchange rate (191) (940) (1,129) (3,575) (2,280)
Cash and cash equivalents at end of period 16,984 32,858 16,984 32,858 36,525
The accompanying notes are an integral part of this consolidated financial
information.
1. Basis of preparation
Benchmark Holdings plc (the 'Company') is a company incorporated and domiciled
in the United Kingdom. These consolidated quarterly financial statements as at
and for the nine months ended 30 June 2024 comprises those of the Company and
its subsidiaries (together referred to as the 'Group').
These consolidated quarterly financial statements do not comprise statutory
accounts within the meaning of section 434 of the Companies Act 2006 and are
unaudited. These financial statements do not include all the information
required for a complete set of IFRS financial statements. However, selected
explanatory notes are included to explain events and transactions that are
significant to an understanding of the changes in the Group's financial
position and performance since the last annual financial statements. The
Group's last annual statutory financial statements as at and for the year
ended 30 September 2023 were prepared in accordance with (i) UK-adopted
International Accounting Standards and (ii) IFRS adopted pursuant to
Regulation (EC) No. 1606/2002 as it applied in the European Union ("Adopted
IFRS") and are available from the Company's website at www.benchmarkplc.com
(http://www.benchmarkplc.com) .
The prior year comparatives are derived from audited financial information for
Benchmark Holdings PLC Group as set out in the Annual Report and Accounts for
the year ended 30 September 2023 and the unaudited financial information in
the Quarterly Financial Report for the nine months ended 30 June 2023. The
comparative figures for the financial year ended 30 September 2023 are not the
Company's statutory accounts for that financial year. Those accounts were
approved by the Directors on 29 November 2023 and have been delivered to the
Registrar of Companies. The audit report received on those accounts was (i)
unqualified and (ii) did not contain a statement under section 498(2) or (3)
of the Companies Act 2006.
Statement of Compliance
These consolidated quarterly financial statements have been prepared and
approved by the Directors in accordance with UK and EU adopted IAS 34 'Interim
Financial Reporting'. These financial statements do not include all of the
information required for the full annual financial statements and should be
read in conjunction with the Group's last annual consolidated financial
statements as at and for the year ended 30 September 2023. These consolidated
quarterly financial statements were approved by the Board of Directors on 22
August 2024.
Going concern
The Group's business activities, together with the factors likely to affect
its future development, performance and position are set out in the Management
Report.
As at 30 June 2024 the Group had net assets of £253.4m (30 September 2023:
£282.6m), including cash of £17.0m (30 September 2023: £36.5m) as set out
in the consolidated balance sheet. The Group made a total loss for the period
of £18.7m (year ended 30 September 2023: loss £21.6m).
The Directors have reviewed forecasts and cash flow projections for a period
of at least 12 months including downside sensitivity assumptions in relation
to trading performance across the Group to assess the impact on the Group's
trading and cash flow forecasts and on the forecast compliance with the
covenants included within the Group's financing arrangements.
In the downside analysis performed, the Directors considered severe but
plausible scenarios on the Group's trading and cash flow forecasts. Key
downside sensitivities modelled included assumptions on slower
commercialisation of SPR shrimp, slower salmon egg sales growth in Chile and
removal of an additional financing opportunity within Genetics, along with
sensitivity of lower sales growth from a possible slower recovery in the
shrimp market in Advanced Nutrition. The post balance sheet restructuring of
the Health business area to focus on the Salmosan business has derisked the
cash utilisation improving the likelihood of cash generation within that
business area for the foreseeable future. Mitigating measures within the
control of management have been identified should they be required in response
to these sensitivities, including reductions in areas of discretionary spend,
tight control over new hires, deferral of capital projects and temporary hold
on R&D for non-imminent products.
On 26 March 2024 an additional facility of £7.5m was added to the existing
RCF with an expiry date of 31 March 2025. The original £20m RCF term remains
unaltered, ending on 27 June 2025.
The Board believes that the current share price materially undervalues the
combined value of Benchmark's businesses and the long-term prospects of the
Company. Consequently, the Board announced on 22 January 2024 the decision
to undertake a formal review of the Company's strategic options, which include
a potential sale of the Company as a whole or of one or more of the individual
business units. The sales process is ongoing, but there are currently no deals
identified or underway and all parts of the business are operating as usual,
so there is no impact on the Directors' assessment of going concern.
Dependent on the outcome of the strategic review the board do not see any
issues with refinancing the debt, given the strong relationships with banks
and the previous success with past refinancing. Based on their assessment of
all of the above, the directors believe it remains appropriate to prepare the
financial statements on a going concern basis. However, while the Directors
remain confident that the current facilities will be renewed or replaced over
the next 12 months, the requirement to do this represents a material
uncertainty that may cast significant doubt on the Group's ability to continue
as a going concern and therefore to continue realising its assets and
discharging its liabilities in the normal course of business. The financial
statements do not include any adjustments that would result from the going
concern assumption being inappropriate
2. Accounting policies
The accounting policies adopted are consistent with those used in preparing
the consolidated financial statements for the financial year ended 30
September 2023.
Taxes on income in the interim periods are accrued using the tax rate that
would be applicable to expected total earnings.
Alternative performance measures ('APMs')
The Directors measure the performance of the Group based on a range of
financial measures, including measures not recognised by UK or EU-adopted
IFRS. These APMs may not be directly comparable with other companies' APMs,
and the Directors do not intend these as a substitute for, or superior to,
IFRS measures.
Directors have presented the performance measures Adjusted EBITDA, Adjusted
Operating Profit, Adjusted Profit Before Tax and Adjusted EBITDA excluding
fair value movement on biological assets because they monitor performance at a
consolidated level using these and believe that these measures are relevant to
an understanding of the Group's financial performance (see note 13).
Furthermore, the Directors also refer to current period results using constant
currency, which are derived by retranslating current period results using the
prior year's foreign exchange rates.
Use of estimates and judgements
The preparation of quarterly financial information requires management to make
certain judgements, estimates and assumptions that affect the application of
accounting policies and the reported amounts of assets and liabilities, income
and expense. Actual amounts may differ from these estimates.
In preparing these quarterly financial statements the significant judgements
made by management in applying the Group's accounting policies and the key
sources of estimation uncertainty were the same as those applied to the
consolidated financial statements for the year ended 30 September 2023.
3. Segment information
Operating segments are reported in a manner consistent with the reports made
to the chief operating decision maker. It is considered that the role of chief
operating decision maker is performed by the Board of Directors.
The Group operates globally and for management purposes is organised into
reportable segments based on the following business areas:
· Genetics - harnesses industry leading salmon breeding
technologies combined with state-of-the-art production facilities to provide a
range of year-round high genetic merit ova.
· Advanced Nutrition - manufactures and provides technically
advanced nutrition and health products to the global aquaculture industry.
· Health - the segment provides health products and services to the
global aquaculture market.
In order to reconcile the segmental analysis to the consolidated income
statement, corporate and inter-segment sales are also shown. Corporate sales
represent revenues earned from recharging certain central costs to the
operating business areas, together with unallocated central costs.
Measurement of operating segment profit or loss
Inter-segment sales are priced along the same lines as sales to external
customers, with an appropriate discount being applied to encourage use of
Group resources at a rate acceptable to local tax authorities. This policy
was applied consistently throughout the current and prior period.
3. Segment information (continued)
Reconciliations of segmental information to IFRS measures
Segmental Revenue
All figures in £000's Q3 2024 Q3 2023 YTD Q3 2024 YTD Q3 2023 FY 2023
(unaudited)
(unaudited)*
(unaudited)
(unaudited)*
(audited)*
Genetics 11,778 14,426 40,173 48,907 65,791
Advanced Nutrition 16,784 16,067 57,197 61,391 78,503
Health 2,168 3,795 13,628 22,872 25,514
Corporate 1,054 1,426 3,752 4,299 5,747
Inter-segment sales (1,095) (1,447) (3,837) (4,340) (5,811)
Total 30,689 34,267 110,913 133,129 169,744
Segmental Adjusted EBITDA
All figures in £000's Q3 2024 Q3 2023 YTD Q3 2024 YTD Q3 2023 FY 2023
(unaudited)
(unaudited)*
(unaudited)
(unaudited)*
(audited)*
Genetics 3,204 3,356 9,127 9,339 14,409
Advanced Nutrition 1,795 3,420 11,671 14,886 18,374
Health 48 (1,022) 2,254 5,628 4,772
Corporate (532) (667) (1,715) (2,706) (3,317)
Total 4,515 5,087 21,337 27,147 34,238
Reconciliation of Reportable Segments Adjusted EBITDA to Loss before
taxation
All figures in £000's Q3 2024 Q3 2023 YTD Q3 2024 YTD Q3 2023 FY 2023
(unaudited)
(unaudited)*
(unaudited)
(unaudited)*
(audited)*
Total reportable segment Adjusted EBITDA 5,047 5,754 23,052 29,853 37,555
Corporate Adjusted EBITDA (532) (667) (1,715) (2,706) (3,317)
Adjusted EBITDA 4,515 5,087 21,337 27,147 34,238
Exceptional - restructuring, acquisition and disposal related items (2,586) (530) (5,065) (3,218) (7,817)
Depreciation and impairment (4,284) (4,702) (13,851) (13,868) (18,713)
Amortisation and impairment (4,140) (4,318) (12,629) (14,230) (18,495)
Net finance costs (2,924) (235) (7,072) (2,445) (7,412)
Loss before taxation (9,419) (4,698) (17,280) (6,614) (18,199)
Reconciliation of segmental information to IFRS measures - Revenue and Loss
before tax
Revenue
Q3 2024 Q3 2023 YTD Q3 2024 YTD Q3 2023 FY 2023
(unaudited)
(unaudited)*
(unaudited)
(unaudited)*
(audited)
Total revenue per segmental information 30,689 34,267 110,913 133,129 169,744
Less: revenue from discontinued operations - (43) - (246) (268)
Consolidated revenue 30,689 34,224 110,913 132,883 169,476
Loss before tax
Q3 2024 Q3 2023 YTD Q3 2024 YTD Q3 2023 FY 2023
(unaudited)
(unaudited)*
(unaudited)
(unaudited)*
(audited)
Profit/(loss) before tax per segmental information (9,419) (4,698) (17,280) (6,614) (18,199)
Less: loss before tax from discontinued operations - 438 - 1,170 5,505
Consolidated Profit/(loss) before tax (9,419) (4,260) (17,280) (5,444) (12,694)
* Results include discontinued operations, see note 5 for further detail
4. Revenue
The Group's operations and main revenue streams are those described in its
financial statements to 30 September 2023. The Group's revenue is derived from
contracts with customers.
Disaggregation of revenue
In the following tables, revenue is disaggregated by primary geographical
market and by sales of goods and services. The table includes a reconciliation
of the disaggregated revenue with the Group's reportable segments (see note
3).
Sale of goods and provision of services
3 months ended 30 June 2024 (unaudited)
All figures in £000's Genetics Advanced Nutrition Health Corporate Inter-segment sales Total Discontinued Continuing
Sale of goods 11,292 16,749 1,723 - - 29,764 - 29,764
Provision of services 480 - 445 - - 925 - 925
Inter-segment sales 6 35 - 1,054 (1,095) - - -
11,778 16,784 2,168 1,054 (1,095) 30,689 - 30,689
3 months ended 30 June 2023 (unaudited)
All figures in £000's Genetics Advanced Nutrition Health Corporate Inter-segment sales Total Discontinued Continuing
Sale of goods 13,523 16,049 2,259 - - 31,831 43 31,788
Provision of services 900 - 1,536 - - 2,436 - 2,436
Inter-segment sales 3 18 - 1,426 (1,447) - - -
14,426 16,067 3,795 1,426 (1,447) 34,267 43 34,224
9 months ended 30 June 2024 (unaudited)
All figures in £000's Genetics Advanced Nutrition Health Corporate Inter-segment sales Total Discontinued Continuing
Sale of goods 38,820 57,090 10,805 - - 106,715 - 106,715
Provision of services 1,341 34 2,823 - - 4,198 - 4,198
Inter-segment sales 12 73 - 3,752 (3,837) - - -
40,173 57,197 13,628 3,752 (3,837) 110,913 - 110,913
9 months ended 30 June 2023 (unaudited)
All figures in £000's Genetics Advanced Nutrition Health Corporate Inter-segment sales Total Discontinued Continuing
Sale of goods 45,727 61,356 15,823 - - 122,906 246 122,660
Provision of services 3,174 - 7,049 - - 10,223 - 10,223
Inter-segment sales 6 35 - 4,299 (4,340) - - -
48,907 61,391 22,872 4,299 (4,340) 133,129 246 132,883
12 months ended 30 September 2023 (audited)
All figures in £000's Genetics Advanced Nutrition Health Corporate Inter-segment sales Total Discontinued Continuing
Sale of goods 61,372 78,449 17,707 - - 157,528 268 157,260
Provision of services 4,409 - 7,807 - - 12,216 - 12,216
Inter-segment sales 10 54 - 5,747 (5,811) - - -
65,791 78,503 25,514 5,747 (5,811) 169,744 268 169,476
4. Revenue (continued)
Primary geographical markets
3 months ended 30 June 2024 (unaudited)
All figures in £000's Genetics Advanced Nutrition Health Corporate Inter-segment sales Total Discontinued Continuing
Norway 5,992 436 999 - - 7,427 - 7,427
Vietnam 12 2,040 - - - 2,052 - 2,052
Iceland 1,962 - 57 - - 2,019 - 2,019
Greece - 1,792 - - - 1,792 - 1,792
Faroe Islands 1,301 - 417 - - 1,718 - 1,718
Venezuela - 1,633 - - - 1,633 - 1,633
Ecuador - 1,395 - - - 1,395 - 1,395
India - 1,331 - - - 1,331 - 1,331
Indonesia 110 1,153 - - - 1,263 - 1,263
Turkey - 1,086 - - - 1,086 - 1,086
Chile 364 - 327 - - 691 - 691
Rest of Europe 948 651 157 - - 1,756 - 1,756
Rest of World 1,083 5,232 211 - - 6,526 - 6,526
Inter-segment sales 6 35 - 1,054 (1,095) - - -
11,778 16,784 2,168 1,054 (1,095) 30,689 - 30,689
3 months ended 30 June 2023 (unaudited)
All figures in £000's Genetics Advanced Nutrition Health Corporate Inter-segment sales Total Discontinued Continuing
Norway 7,190 349 3,155 - - 10,694 - 10,694
Vietnam - 2,445 - - - 2,445 - 2,445
Iceland 1,166 - - - - 1,166 - 1,166
Greece - 1,698 - - - 1,698 - 1,698
Faroe Islands 1,668 - 116 - - 1,784 - 1,784
Venezuela - 680 - - - 680 - 680
Ecuador 9 1,936 - - - 1,945 - 1,945
India - 671 - - - 671 - 671
Indonesia 98 705 - - - 803 - 803
Turkey 54 1,208 - - - 1,262 - 1,262
Chile 332 1 291 - - 624 - 624
Rest of Europe 1,166 794 93 - - 2,053 - 2,053
Rest of World 2,740 5,562 140 - - 8,442 43 8,399
Inter-segment sales 3 18 - 1,426 (1,447) - - -
14,426 16,067 3,795 1,426 (1,447) 34,267 43 34,224
4. Revenue (continued)
Primary geographical markets (continued)
9 months ended 30 June 2024 (unaudited)
All figures in £000's Genetics Advanced Nutrition Health Corporate Inter-segment sales Total Discontinued Continuing
Norway 22,422 885 8,158 - - 31,465 - 31,465
Vietnam 12 6,746 - - - 6,758 - 6,758
Iceland 4,673 - 57 - - 4,730 - 4,730
Greece - 5,451 - - - 5,451 - 5,451
Faroe Islands 4,011 - 919 - - 4,930 - 4,930
Venezuela 157 2,567 - - - 2,724 - 2,724
Ecuador 40 4,617 - - - 4,657 - 4,657
India - 8,065 - - - 8,065 - 8,065
Indonesia 268 3,289 - - - 3,557 - 3,557
Turkey 9 5,300 - - - 5,309 - 5,309
Chile 3,357 - 1,369 - - 4,726 - 4,726
Rest of Europe 2,998 4,094 302 - - 7,394 - 7,394
Rest of World 2,214 16,110 2,823 - - 21,147 - 21,147
Inter-segment sales 12 73 - 3,752 (3,837) - - -
40,173 57,197 13,628 3,752 (3,837) 110,913 - 110,913
9 months ended 30 June 2023 (unaudited)
All figures in £000's Genetics Advanced Nutrition Health Corporate Inter-segment sales Total Discontinued Continuing
Norway 30,251 691 17,607 - - 48,549 - 48,549
Vietnam - 7,470 - - - 7,470 - 7,470
Iceland 4,138 - - - - 4,138 - 4,138
Greece - 5,969 - - - 5,969 - 5,969
Faroe Islands 4,988 - 464 - - 5,452 - 5,452
Venezuela 43 1,584 - - - 1,627 - 1,627
Ecuador 38 5,508 - - - 5,546 - 5,546
India - 7,696 - - - 7,696 - 7,696
Indonesia 436 2,815 - - - 3,251 - 3,251
Turkey 56 5,940 - - - 5,996 - 5,996
Chile 1,465 12 633 - - 2,110 - 2,110
Rest of Europe 3,486 4,162 136 - - 7,784 - 7,784
Rest of World 4,000 19,509 4,032 - - 27,541 246 27,295
Inter-segment sales 6 35 - 4,299 (4,340) - - -
48,907 61,391 22,872 4,299 (4,340) 133,129 246 132,883
4. Revenue (continued)
Primary geographical markets (continued
12 months ended 30 September 2023 (audited)
All figures in £000's Genetics Advanced Nutrition Health Corporate Inter-segment sales Total Discontinued Continuing
Norway 39,007 897 19,596 - - 59,500 - 59,500
Vietnam - 11,229 - - - 11,229 - 11,229
Iceland 7,343 - - - - 7,343 - 7,343
Greece - 6,759 - - - 6,759 - 6,759
Faroe Islands 6,160 - 718 - - 6,878 - 6,878
Venezuela 43 2,019 - - - 2,062 - 2,062
Ecuador 38 7,257 - - - 7,295 - 7,295
India - 9,743 - - - 9,743 - 9,743
Indonesia 637 4,099 - - - 4,736 - 4,736
Turkey 93 7,009 - - - 7,102 - 7,102
Chile 1,824 12 991 - - 2,827 - 2,827
Rest of Europe 5,427 4,941 177 - - 10,545 - 10,545
Rest of World 5,209 24,484 4,032 - - 33,725 268 33,457
Inter-segment sales 10 54 - 5,747 (5,811) - - -
65,791 78,503 25,514 5,747 (5,811) 169,744 268 169,476
5. Discontinued activities
During FY23, the group divested its tilapia business for consideration of USD
1 in a management buy out. Consequently, these operations were classified as
discontinued in the prior year and a restatement of the consolidated income
statement.
Summary of restatement of Q3 FY23 results as reported in Q3 FY24 financial
statements
Continuing operations Discontinued operations
All figures in £000's Revenue Adjusted EBITDA Loss from continuing operations Loss from discontinued operations
As stated in Q3 FY23 financial statements 133,129 27,147 (8,021) -
Reclassified in Q1 (73) 368 453 (453)
Reclassified in Q2 (130) 194 279 (279)
Reclassified in Q3 (43) 353 438 (438)
As stated in Q3 FY24 financial statements 132,883 28,062 (6,851) (1,170)
Results from discontinued operations
Q3 FY24 Q3 FY23 YTD Q3 FY24 YTD Q3 FY23 FY23
£000 £000 £000 £000 £000
Revenue - 43 - 246 268
Cost of sales - (275) - (755) (973)
Gross profit - (232) - (509) (705)
Research and development costs - (3) - (16) (59)
Other operating costs - (118) - (390) (490)
Share of profit of equity-accounted investees, net of tax - - - - -
Adjusted EBITDA - (353) - (915) (1,254)
Exceptional loss on disposal - - - - (3,913)
EBITDA - (353) - (915) (5,167)
Depreciation and impairment - (76) - (228) (304)
Amortisation and impairment - - - - -
Operating loss / Loss before taxation - (429) - (1,143) (5,471)
Net finance costs - (9) - (27) (34)
Loss before taxation - (438) - (1,170) (5,505)
Tax on loss - - - - -
Loss from discontinued operations - (438) - (1,170) (5,505)
Exceptional items within discontinued operations
Q3 FY24 Q3 FY23 YTD Q3 FY24 YTD Q3 FY23 FY23
£000 £000 £000 £000 £000
Profit/(loss) on disposal of subsidiaries - - - - 3,774
Profit/(loss) on other asset disposals - - - - 139
Total exceptional recognised - - - - 3,913
Results from discontinued operations by segment
The results from discontinued operations relate solely to the Genetics
operating segment.
6. Exceptional items from continuing operations -
restructuring/acquisition and disposal related items
Items that are material because of their size or nature, are non-recurring and
whose significance is sufficient to warrant separate disclosure and
identification within the consolidated financial statements are referred to as
exceptional items. The separate reporting of exceptional items helps to
provide an understanding of the Group's underlying performance.
All figures in £000's Q3 2024 Q3 2023 YTD Q3 2024 YTD Q3 2023 FY 2023
(unaudited)
(unaudited)
(unaudited)
(unaudited)
(audited)
Acquisition related items - 579 - 579 652
Exceptional restructuring costs 1,957 152 4,612 2,825 3,470
Disposal related items 629 (201) 452 (186) (218)
Total exceptional items 2,586 530 5,065 3,218 3,904
In Q3 2023, YTD Q3 2023 and FY 2023 acquisition related items comprise fees
incurred in the year in connection with an aborted acquisition.
Exceptional restructuring costs include £1.2m in the quarter (Q3 2023 £nil)
and £3.0m YTD (YTD 2023: £nil) relating to the formal review of the
Company's strategic options and the potential sale. Other restructuring costs
include £0.8m for the quarter (Q3 2023: £0.1m) and £1.6m YTD (YTD 2023
£0.2m, FY 2023 £0.9m). In addition to this in FY 23 there were £2.6m (Q3
2023: £0.1m, YTD 2023: £2.6m) of legal and professional costs in relation to
preparing for listing the Group on the Oslo stock exchange.
Disposal related items in the quarter relate to uninsured culling of
broodstock and clean-up costs of £0.6m. Additionally, there was a gain of
£0.2m in the YTD for the sale of equipment in relation to a business disposed
of in prior years. In FY 2023 there was a credit of £0.2m for additional
contingent consideration received and receivable relating to the disposal of a
business from 2020, which was slightly offset by other disposal related costs.
7. Net finance costs from continuing operations
All figures in £000's Q3 2024 Q3 2023 YTD Q3 2024 YTD Q3 2023 FY 2023
(unaudited)
Restated
(unaudited)
Restated
(audited)
(unaudited)
(unaudited)
Interest received on bank deposits 65 155 351 472 627
Foreign exchange gains on financing activities - 158 - 158 158
Foreign exchange gains on operating activities 547 1,363 1,554 6,409 4,709
Cash flow hedges - reclassified from OCI - 273 - 565 -
Cash flow hedges - ineffective portion of changes in fair value - 798 - 3,158 2,176
Finance income 612 2,746 1,905 10,762 7,670
Leases (interest portion) (385) (381) (1,075) (1,235) (1,620)
Foreign exchange losses on operating activities (620) (175) (666) (6,034) (4,547)
Interest expense on financial liabilities measured at amortised cost (2,531) (2,416) (7,236) (5,911) (8,881)
Finance costs (3,536) (2,972) (8,977) (13,180) (15,048)
Net finance costs recognised in profit or loss (2,924) (226) (7,072) (2,418) (7,378)
8. Taxation
All figures in £000's Q3 2024 Q3 2023 YTD Q3 2024 YTD Q3 2023 FY 2023
(unaudited)
(unaudited)
(unaudited)
(unaudited)
(audited)
Analysis of charge in period
Current tax:
Current income tax expense on profits for the period 1,617 823 4,243 3,658 6,178
Adjustment in respect of prior periods - - - - (880)
Total current tax charge 1,617 823 4,243 3,658 5,298
Deferred tax:
Origination and reversal of temporary differences (1,088) (899) (2,804) (2,251) (1,933)
Total deferred tax charge/(credit) (1,088) (899) (2,804) (2,251) (1,933)
- -
Total tax charge 529 (76) 1,439 1,407 3,365
9. Loss per share
Basic loss per share is calculated by dividing the loss attributable to
ordinary equity holders of the Company by the weighted average number of
ordinary shares in issue during the period.
Q3 2024 Q3 2023 YTD Q3 2024 YTD Q3 2023 FY 2023
(unaudited)
Restated
(unaudited)
Restated
(audited)
(unaudited)
(unaudited)
Loss attributable to equity holders of the parent (£000)
Continuing operations (9,913) (4,322) (18,861) (7,593) (17,641)
Discontinued operations - (438) - (1,170) (5,505)
Total (9,913) (4,760) (18,861) (8,763) (23,146)
Weighted average number of shares in issue (thousands) 739,708 739,300 739,507 729,437 731,935
Basic loss per share (pence)
Continuing operations (1.34) (0.58) (2.55) (1.04) (2.41)
Discontinued operations - (0.06) - (0.16) (0.75)
Total (1.34) (0.64) (2.55) (1.20) (3.16)
Diluted loss per share is calculated by adjusting the weighted average number
of ordinary shares outstanding to assume conversion of all dilutive potential
ordinary shares. This is done by calculating the number of shares that could
have been acquired at fair value (determined as the average market price of
the Company's shares for the period) based on the monetary value of the
subscription rights attached to outstanding share options and warrants. The
number of shares calculated above is compared with the number of shares that
would have been issued assuming the exercise of the share options and
warrants.
Therefore, the Company is required to adjust the earnings per share
calculation in relation to the share options that are in issue under the
Company's share-based incentive schemes, and outstanding warrants. However, as
any potential ordinary shares would be anti-dilutive due to losses being made
there is no difference between Basic loss per share and Diluted loss per share
for any of the periods being reported.
A total of 13,716,299 potential ordinary shares have not been included within
the calculation of statutory diluted loss per share for the year (30 September
2023: 8,948,132 and 30 June 2023: 5,988,043). These potential ordinary shares
could dilute earnings/loss per share in the future.
10. Assets held for sale
During 2022, management committed to sell certain property, plant and
equipment held within the Health business area. The property concerned was
longer required by the business and the decision was made to sell. The market
value of the property fell during the period and a further impairment charge
of £200,000 was incurred to write the asset down to its current market value
of £300,000 (30 September 2023: £850,000). The property was sold for
£300,000 on 28 March 2024.
There were no liabilities directly associated with the assets held for sale.
Assets held for sale YTD Q3 2024 YTD Q3 2023 FY 2023
(unaudited)
(unaudited)
(audited)
All figures in £000's
Property, plant and equipment - 850 850
Total Assets held for sale - 850 850
11. Loans and borrowings
YTD Q2 2024 YTD Q3 2023 FY 2023
(unaudited)
(unaudited)
(audited)
All figures in £000's
Non-Current
2025 750m NOK Loan notes 55,706 53,382 57,604
Bank borrowings 14,642 15,746 16,799
Unamortised debt issue costs (111) - (742)
Lease liabilities 6,245 8,832 8,293
76,482 77,960 81,954
Current
Bank borrowings 11,779 9,439 9,320
Unamortised debt issue costs (1,093) - (842)
Lease liabilities 4,885 12,318 11,567
15,571 21,757 20,045
Total loans and borrowings 92,053 99,717 101,999
The Group has an unsecured floating rate listed green bond of NOK 750m in
issue. The bond which matures in September 2025, has a coupon of three-month
NIBOR + 6.50% p.a. with quarterly interest payments, and is listed on the Oslo
Stock Exchange.
The Group has a secured GBP 20m RCF provided by DNB Bank ASA, maturing on 27
June 2025. This facility was extended on the same terms in March 2024 by GBP
7.5m, to a total facility of GBP 27.5m, with the GBP 7.5m extension maturing
on 27 March 2025. The margin on this combined facility is a minimum of 2.75%
and a maximum of 3.25%, dependent upon the leverage of the Group above the
relevant risk-free reference or IBOR rates depending on which currency is
drawn. As at 30 June 2024 there was £17.25m undrawn.
Additionally, Benchmark Genetics Salten AS had the following loans (which are
ring-fenced debt without recourse to the remainder of the Group) at 30 June
2024:
• term loan with Nordea Bank with a balance of NOK 160.5m, which
has a maturity date of five years ending 15 January 2028 and an interest rate
of 2.5% above three-month NIBOR.
• twelve month working capital facility of NOK 20.0m provided by
Nordea Bank Norge Abp. This was undrawn at 30 June 2024
• term loan with a balance of NOK 32.1m provided by Innovasjon
Norge. The loan is a 12-and-a-half year term loan maturing in March 2031. The
interest rate on this loan at 30 June 2024 was 6.7%
• an additional 15-year term loan with a balance of NOK 9.5m
provided by Innovasjon Norge and maturing in July 2038. The interest rate on
this loan at 30 June 2024 was 6.7%
• a loan of NOK 15.5m provided by the minority shareholder Salten
Stamfisk AS. The loan attracts interest at 2.5% above three-month NIBOR and is
repayable on maturity of the Nordea loan above.
12. Share capital and additional paid-in share capital
Number Share Capital Additional paid-in
share capital
Allotted, called up and fully paid £000 £000
Ordinary shares of 0.1 pence each
Balance at 30 September 2023 739,352,390 739 37,428
Exercise of share options 426,253 1 62
Balance at 31 March 2024 739,778,643 740 37,490
13. Alternative performance measures and other metrics
Management has presented the performance measures EBITDA, Adjusted EBITDA,
Adjusted EBITDA before fair value movement in biological assets, Adjusted
Operating Profit and Adjusted Profit Before Tax because it monitors
performance at a consolidated level using these and believes that these
measures are relevant to an understanding of the Group's financial
performance.
Adjusted EBITDA which reflects underlying profitability, is earnings before
interest, tax, depreciation, amortisation, impairment, and exceptional items
and is shown on the Income Statement.
Adjusted EBITDA before fair value movements in biological assets, which is
Adjusted EBITDA before the non-cash fair value movements in biological assets
arising from their revaluation in line with International Accounting
Standards.
Adjusted Operating Profit is operating loss before exceptional items and
amortisation and impairment of intangible assets excluding development costs
as reconciled below.
Adjusted Profit Before Tax is earnings before tax, amortisation and impairment
of intangibles assets excluding development costs, and exceptional items as
reconciled below. These measures are not defined performance measures in IFRS.
The Group's definition of these measures may not be comparable with similarly
titled performance measures and disclosures by other entities.
Reconciliation of Adjusted Operating Profit/(loss) to Operating Profit/(loss)
All figures in £000's Q3 2024 Q3 2023 YTD Q3 2024 YTD Q3 2023 FY 2023
(unaudited)
Restated
(unaudited)
Restated
(audited)
(unaudited)
(unaudited)
Revenue 30,689 34,224 110,913 132,883 169,476
Cost of sales (15,071) (16,715) (56,047) (66,052) (82,726)
Gross profit 15,618 17,509 54,866 66,831 86,750
Research and development costs (1,409) (1,493) (4,468) (4,478) (6,069)
Other operating costs (9,879) (10,521) (30,231) (34,292) (45,157)
Depreciation and impairment (4,284) (4,626) (13,851) (13,640) (18,409)
Amortisation of capitalised development costs (604) (606) (1,815) (1,833) (2,437)
Share of profit/(loss) of equity accounted investees net of tax 185 (55) 1,170 1 (32)
Adjusted operating (loss)/profit (373) 208 5,671 12,589 14,646
Exceptional - restructuring, acquisition and disposal related items (2,586) (530) (5,065) (3,218) (3,904)
Amortisation and impairment of intangible assets excluding development costs (3,536) (3,712) (10,814) (12,397) (16,058)
Operating loss (6,495) (4,034) (10,208) (3,026) (5,316)
13. Alternative performance measures and other metrics (continued)
Reconciliation of Loss Before Taxation to Adjusted Profit Before Tax
All figures in £000's Q3 2024 Q3 2023 YTD Q3 2024 YTD Q3 2023 FY 2023
(unaudited)
Restated
(unaudited)
Restated
(audited)
(unaudited)
(unaudited)
Loss before taxation (9,419) (4,260) (17,280) (5,444) (12,694)
Exceptional - restructuring, acquisition and disposal related items 2,586 530 5,065 3,218 3,904
Amortisation and impairment of intangible assets excluding development costs 3,536 3,712 10,814 12,397 16,058
Adjusted (loss)profit before tax (3,297) (18) (1,401) 10,171 7,268
Other Metrics
All figures in £000's Q3 2024 Q3 2023 YTD Q3 2024 YTD Q3 2023 FY 2023
(unaudited)
Restated
(unaudited)
Restated
(audited)
(unaudited)
(unaudited)
Total R&D Investment
Research and development costs
- Continuing operations 1,409 1,493 4,468 4,478 6,069
- Discontinued operations - 3 - 16 59
Internal capitalised development costs 56 183 150 380 632
Total R&D investment 1,465 1,679 4,618 4,874 6,760
All figures in £000's Q3 2024 Q3 2023 YTD Q3 2024 YTD Q3 2023 FY 2023
(unaudited)
Restated
(unaudited)
Restated
(audited)
(unaudited)
(unaudited)
Adjusted EBITDA excluding fair value movement in biological assets
Adjusted EBITDA 4,515 5,440 21,337 28,062 35,492
Exclude fair value movement 73 (1,457) 580 (1,704) 103
Adjusted EBITDA excluding fair value movement in biological assets 4,588 3,983 21,917 26,358 35,595
Liquidity
A key financial covenant is a minimum liquidity of £10m, defined as cash plus
undrawn facilities.
All figures in £000's 30 June 2024 (unaudited) 30 June 2023 (unaudited) FY 2023
(audited)
Cash and cash equivalents 16,984 32,858 36,525
Undrawn bank facility 17,250 12,250 12,250
Total liquidity 34,234 45,108 48,775
The undrawn bank facility relates to the RCF facility. At 30 June 2024,
£10.25m of the RCF was drawn (30 June 2023: £7.75m, 30 September 2023:
£7.75m), leaving £17.25m undrawn (30 June 2023: £12.25m, 30 September 2023:
£12.25m).
14. Net debt
Net debt is cash and cash equivalents less loans and borrowings.
30 June 2024 30 June 2023 30 September 2023
All figures in £000's (unaudited) (unaudited) (audited)
Cash and cash equivalents 16,984 32,858 36,525
Loans and borrowings (excluding lease liabilities) - current (10,686) (9,439) (8,478)
Loans and borrowings (excluding lease liabilities) - non-current (70,237) (69,128) (73,661)
Net debt excluding lease liabilities (63,939) (45,709) (45,614)
Lease liabilities - current (4,885) (12,318) (11,567)
Lease liabilities - non-current (6,245) (8,832) (8,293)
Net debt (75,069) (66,859) (65,474)
15. Post Balance sheet event
After the period end in July 2024, the decision was made to restructure the
Health business area. The restructuring exercise will reduce operating
expenditure in the business area by streamlining resource to focus on the
Salmosan and Purisan business whilst discussions with customers about
investing in the new operating models continue. The technical capability to
roll out the CleanTreat® infrastructure onto customer owned platforms upon
getting customer commitment is being retained.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END QRTPPUCWRUPCPUG